Macromolecular Modelling and Docking Simulations for the Discovery of Selective GPER Ligands

详细信息    查看全文

• 作者：Camillo Rosano ; Marco Ponassi ; Maria Francesca Santolla ; Assunta Pisano…
• 关键词：drug design ; GPCRs ; GPER ; molecular modelling ; structural bioinformatics
• 刊名：The AAPS Journal
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：18
• 期：1
• 页码：41-46
• 全文大小：1,596 KB
• 参考文献：1.Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signalling. J Biol Chem. 2001;276:36869–72.PubMed CrossRef
  2.Selye H. Stress and the general adaptation syndrome. Br Med J. 1950;1:1383–92.PubMed PubMedCentral CrossRef
  3.Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M. Multiple actions of steroid hormones--a focus on rapid, nongenomic effects. Pharmacol Rev. 2000;52:513–56.PubMed
  4.Carmeci C, Thompson DA, Ring HZ, Francke U, Weigel RJ. Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics. 1997;45:607–17.PubMed CrossRef
  5.Prossnitz ER, Hathaway HJ. What have we learned about GPER function in physiology and disease from knockout mice? J Steroid Biochem Mol Biol. 2015;153:114–26.PubMed CrossRef
  6.Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol. 2010;204:105–14.PubMed CrossRef
  7.Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J. 2009;28:523–32.PubMed PubMedCentral CrossRef
  8.De Francesco EM, Pellegrino M, Santolla MF, Lappano R, Ricchio E, Abonante S, et al. GPER mediates activation of HIF1α/VEGF signaling by estrogens. Cancer Res. 2014;74:4053–64.PubMed CrossRef
  9.Madeo A, Maggiolini M. Nuclear alternate estrogen receptor GPR30 mediates 17b-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res. 2010;70:6036–46.PubMed CrossRef
  10.Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, et al. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res. 2006;12:6359–66.PubMed CrossRef
  11.Smith HO, Leslie KK, Singh MM, Qualls CR, Revankar CM, Joste NE, et al. GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol. 2007;196(386):e11.
  12.Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, et al. GPR30 predicts poor survival for ovarian cancer. Gynecol Oncol. 2009;114:465–71.PubMed PubMedCentral CrossRef
  13.Rosano C, Lappano R, Santolla MF, Ponassi M, Donadini A, Maggiolini M. Recent advances in the rationale design of GPER ligands. Curr Med Chem. 2012;19:6199–206.PubMed CrossRef
  14.Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res. 2000;28:235–42.PubMed PubMedCentral CrossRef
  15.Zhang J, Yang J, Jang R, Zhang Y. GPCR-I-TASSER: a hybrid approach to G protein-coupled receptor structure modeling and the application to the human genome. Structure. 2015;23:1538–49.PubMed CrossRef
  16.Bjarnadóttir TK, Gloriam DE, Hellstrand SH, Kristiansson H, Fredriksson R, Schiöth HB. Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. Genomics. 2006;88:263–73.PubMed CrossRef
  17.Rosano C. Molecular model of hexokinase binding to the outer mitochondrial membrane porin (VDAC1): implication for the design of new cancer therapies. Mitochondrion. 2011;11:513–9.PubMed CrossRef
  18.Clothia C, Lesk AM. The relation between the divergence of sequence and structure in proteins. EMBO J. 1986;5:823–6.
  19.Tramontano A. Homology modelling with low sequence identity. Methods. 1998;14:293–300.PubMed CrossRef
  20.Kufareva I, Katritch V, Participants of GPCR Dock 2013, Stevens RC, Abagyan R. Advances in GPCR modeling evaluated by the GPCR Dock 2013 assessment: meeting new challenges. Structure. 2013;22:1120–39.CrossRef
  21.Moult J, Fidelis K, Kryshtafovych A, Schwede T, Tramontano A. Critical assessment of methods of protein structure prediction (CASP) - round X. Proteins. 2014;82 Suppl 2:1–6.PubMed PubMedCentral CrossRef
  22.Arnold K, Kiefer F, Kopp J, Battey JN, Podvinec M, Westbrook JD, et al. The Protein Model Portal. J Struct Funct Genom. 2009;10:1–8.CrossRef
  23.Méndez-Luna D, Martínez-Archundia M, Maroun RC, Ceballos-Reyes G, Fragoso-Vázquez MJ, González-Juárez DE, et al. Deciphering the GPER/GPR30-agonist and antagonists interactions using molecular modeling studies, molecular dynamics, and docking simulations. J Biomol Struct Dyn. 2015;33:2161–72.PubMed CrossRef
  24.Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol. 2006;4:207–12.CrossRef
  25.Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, Nayak TK, et al. In vivo effects of a GPR30 antagonist. Nat Chem Biol. 2009;5:421–7.PubMed PubMedCentral CrossRef
  26.Ramesh C, Nayak TK, Burai R, Dennis MK, Hathaway HJ, Sklar LA, et al. Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30. J Med Chem. 2010;53:1004–14.PubMed PubMedCentral CrossRef
  27.Lappano R, Rosano C, De Marco P, De Francesco EM, Pezzi V, Maggiolini M. Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Mol Cell Endocrinol. 2010;320:162–70.PubMed CrossRef
  28.Dennis MK, Field AS, Burai R, Ramesh C, Petrie WK, Bologa CG, et al. Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. J Steroid Biochem Mol Biol. 2011;127:358–66.PubMed PubMedCentral CrossRef
  29.Lappano R, Rosano C, Santolla MF, Pupo M, De Francesco EM, De Marco P, et al. Two novel GPER agonists induce gene expression changes and growth effects in cancer cells. Curr Cancer Drug Targets. 2012;12:531–42.PubMed CrossRef
  30.Lappano R, Santolla MF, Pupo M, Sinicropi MS, Caruso A, Rosano C, et al. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells. Breast Cancer Res. 2012;14:R12.PubMed PubMedCentral CrossRef
  31.Santolla MF, De Francesco EM, Lappano R, Rosano C, Abonante S, Maggiolini M. Niacin activates the G protein estrogen receptor (GPER)-mediated signalling. Cell Signal. 2014;26:1466–75.PubMed CrossRef
  32.Chimento A, Casaburi I, Rosano C, Avena P, De Luca A, Campana C, et al. Oleuropein and hydroxytyrosol activate GPER/ GPR30-dependent pathways leading to apoptosis of ER-negative SKBR3 breast cancer cells. Mol Nutr Food Res. 2014;58:478–89.PubMed CrossRef
  33.Maggiolini M, Santolla MF, Avino S, Aiello F, Rosano C, Garofalo A, et al. Identification of two benzopyrroloxazines acting as selective GPER antagonists in breast cancer cells and cancer-associated fibroblasts. Future Med Chem. 2015;7:437–48.PubMed CrossRef
  34.Lappano R, Rosano C, Pisano A, Santolla MF, De Francesco EM, De Marco P, et al. A calixpyrrole derivative acts as a GPER antagonist: mechanisms and models. Dis Model Mech. 2015. doi:10.​1242/​dmm.​021071 .PubMed PubMedCentral
  35.Sinicropi MS, Lappano R, Caruso A, Santolla MF, Pisano A, Rosano C, et al. (6
  omo-1,4-dimethyl-9H-carbazol-3-yl-methylene)-hydrazine (carbhydraz) acts as a GPER agonist in breast cancer cells. Curr Top Med Chem. 2015;15:1035–42.PubMed CrossRef
  36.Owman C, Blay P, Nilsson C, Lolait SJ. Cloning of human cDNA encoding a novel heptaelix receptor expressed in Burkitt’s lymphoma and widely distributed in brain and peripheral tissues. Biochem Biophys Res Commun. 1996;228:285–92.PubMed CrossRef
  37.Prossnitz ER, Arterburn JB. International Union of Basic and Clinical Pharmacology. XCVII. G protein-coupled estrogen receptor and its pharmacologic modulators. Pharmacol Rev. 2015;67:505–40.PubMed CrossRef
  38.Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science. 2000;289:739–45.PubMed CrossRef
  39.Kim DE, Chivian D, Baker D. Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res. 2004;32(Web Server issue): W526–W531.
  40.Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993;234:779–815.PubMed CrossRef
  41.Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK - a program to check the stereochemical quality of protein structures. J App Crystallogr. 1993;26:283–91.CrossRef
  42.Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity. J Comput Chem. 2009;16:2785–91.CrossRef
  43.Filardo EJ, Quinn JA, Bland KI, Frackelton Jr AR. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol. 2000;10:1649–60.CrossRef
  44.Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signalling. Science. 2005;307:1625–30.PubMed CrossRef
  45.Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Andò S, et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17β-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol. 2006;20:631–46.PubMed CrossRef
  46.Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, Carpino A, et al. 17β-Estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein coupled-receptor GPR30. Mol Pharmacol. 2006;70:1414–23.PubMed CrossRef
  47.Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998;95:927–37.PubMed CrossRef
  48.Albini A, Rosano C, Angelini G, Amaro A, Esposito AI, Maramotti S, et al. Exogenous hormonal regulation in breast cancer cells by phytoestrogens and endocrine disruptors. Curr Med Chem. 2014;21:1129–45.PubMed PubMedCentral CrossRef
  49.Papalia T, Lappano R, Baratucci A, Pisano A, Bruno G, Santolla MF, et al. A Bodipy as a luminescent probe for detection of the g protein estrogen receptor (GPER). Org Biomol Chem. 2015. doi:10.​1039/​C5OB01827G .PubMed
  50.Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov. 2011;10:47–60.PubMed CrossRef
  
• 作者单位：Camillo Rosano (1)
  Marco Ponassi (1)
  Maria Francesca Santolla (2)
  Assunta Pisano (2)
  Lamberto Felli (3)
  Adele Vivacqua (2)
  Marcello Maggiolini (2)
  Rosamaria Lappano (2)
  
  1. UOS Proteomics IRCCS AOU San Martino- IST National Institute for Cancer Research, Largo R. Benzi 10, 16132, Genoa, Italy
  2. Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, via Bucci, 87036, Rende, Cosenza, Italy
  3. Department of Orthopedical Surgery, University of Genoa, Largo R. Benzi 10, 16132, Genoa, Italy
  
• 刊物主题：Pharmacology/Toxicology; Biochemistry, general; Biotechnology; Pharmacy;
• 出版者：Springer US
• ISSN：1550-7416

文摘

Estrogens influence multiple physiological processes and are implicated in many diseases as well. Cellular responses to estrogens are mainly mediated by the estrogen receptors (ER)α and ERβ, which act as ligand-activated transcription factors. Recently, a member of the G protein-coupled receptor (GPCR) superfamily, namely GPER/GPR30, has been identified as a further mediator of estrogen signalling in different pathophysiological conditions, including cancer. Today, computational methods are commonly used in all areas of health science research. Among these methods, virtual ligand screening has become an established technique for hit discovery and optimization. The absence of an established three-dimensional structure of GPER promoted studies of structure-based drug design in order to build reliable molecular models of this receptor. Here, we discuss the results obtained through the structure-based virtual ligand screening for GPER, which allowed the identification and synthesis of different selective agonist and antagonist moieties. These compounds led significant advances in our understanding of the GPER function at the cellular, tissue, and organismal levels. In particular, selective GPER ligands were critical toward the evaluation of the role elicited by this receptor in several pathophysiological conditions, including cancer. Considering that structure-based approaches are fundamental in drug discovery, future research breakthroughs with the aid of computer-aided molecular design and chemo-bioinformatics could generate a new class of drugs that, acting through GPER, would be useful in a variety of diseases as well as in innovative anticancer strategies. Key words drug design GPCRs GPER molecular modelling structural bioinformatics